Loading
KC1036 is an experimental small-molecule drug from Beijing Konruns Pharmaceutical in phase 3 trials for oesophageal cancer, ewing sarcoma and thymoma and thymic carcinoma, with its target not yet stated publicly.
KC1036 is a small-molecule drug developed by Beijing Konruns Pharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: For patients weighing between 30 kg and less than 50 kg, administer 40 mg QD of KC1036. For patients weighing between 50 kg and less than 70 kg, administer 50 mg QD of KC1036. For patients weighing 70 kg or more, administer 60 mg QD of KC10. It is the investigational product in 5 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06194734 (A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Oesophageal Cancer), in oesophageal cancer, ewing sarcoma and thymoma and thymic carcinoma. The largest, NCT06194734, plans to enrol 490 participants with primary completion expected 2026-12-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.KC1036 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"KC1036" OR ABSTRACT:"KC1036") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KC1036, not a curated reading list.
Shares Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3), Thymoma and thymic carcinoma and the tag pipeline.
Shares Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3), Thymoma and thymic carcinoma and the tag pipeline.
Shares Thymic carcinoma, Thymoma and thymic carcinoma and the tag pipeline.
Shares Shanghai Kechow Pharma and the tag pipeline.
Shares A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma, A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer, A Study of KC1036 in Patients with Advanced Thymic Tumors, KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer.
Shares Ewing sarcoma and the tag pipeline.
Shares Oesophageal cancer and the tag pipeline.
Shares Oesophageal cancer and the tag pipeline.